These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23943638)

  • 1. BMS-927711 for the acute treatment of migraine.
    Bigal ME
    Cephalalgia; 2014 Feb; 34(2):90-2. PubMed ID: 23943638
    [No Abstract]   [Full Text] [Related]  

  • 2. CGRP-receptor antagonists--a fresh approach to migraine therapy?
    Durham PL
    N Engl J Med; 2004 Mar; 350(11):1073-5. PubMed ID: 15014178
    [No Abstract]   [Full Text] [Related]  

  • 3. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial.
    Marcus R; Goadsby PJ; Dodick D; Stock D; Manos G; Fischer TZ
    Cephalalgia; 2014 Feb; 34(2):114-25. PubMed ID: 23965396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Medications for the Treatment of Migraine.
    Ceriani CEJ; Wilhour DA; Silberstein SD
    Headache; 2019 Oct; 59(9):1597-1608. PubMed ID: 31559638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?
    Tfelt-Hansen P; Loder E
    Headache; 2019 Jan; 59(1):113-117. PubMed ID: 30451300
    [No Abstract]   [Full Text] [Related]  

  • 6. Everything old is new again.
    Freitag FG
    Headache; 2021 Sep; 61(8):1286. PubMed ID: 34350590
    [No Abstract]   [Full Text] [Related]  

  • 7. Rimegepant (Nurtec ODT) for Acute Treatment of Migraine.
    JAMA; 2020 Sep; 324(9):890-891. PubMed ID: 32870296
    [No Abstract]   [Full Text] [Related]  

  • 8. Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine.
    Luo G; Chen L; Conway CM; Denton R; Keavy D; Signor L; Kostich W; Lentz KA; Santone KS; Schartman R; Browning M; Tong G; Houston JG; Dubowchik GM; Macor JE
    J Med Chem; 2012 Dec; 55(23):10644-51. PubMed ID: 23153230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of BMS-927711 and other gepants vs triptans: there seem to be other players besides CGRP.
    Pascual J
    Cephalalgia; 2014 Oct; 34(12):1028-9. PubMed ID: 24615704
    [No Abstract]   [Full Text] [Related]  

  • 10. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
    Lipton RB; Croop R; Stock EG; Stock DA; Morris BA; Frost M; Dubowchik GM; Conway CM; Coric V; Goadsby PJ
    N Engl J Med; 2019 Jul; 381(2):142-149. PubMed ID: 31291516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcitonin gene-related peptide - beyond migraine prophylaxis.
    Olesen J; Ashina M
    Nat Rev Neurol; 2019 Oct; 15(10):562-564. PubMed ID: 31488896
    [No Abstract]   [Full Text] [Related]  

  • 12. Rimegepant (Nurtec ODT) for acute treatment of migraine.
    Med Lett Drugs Ther; 2020 May; 62(1597):70-72. PubMed ID: 32555113
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacology and Pharmacokinetics of Ubrogepant: A Potent, Selective Calcitonin Gene-Related Peptide Receptor Antagonist for the Acute Treatment of Migraine.
    Blumenfeld AM; Edvinsson L; Jakate A; Banerjee P
    J Fam Pract; 2020; 69(1 Suppl):S8-S12. PubMed ID: 32053714
    [No Abstract]   [Full Text] [Related]  

  • 14. Reporting withdrawals due to adverse events in single-attack acute migraine clinical trials.
    Tfelt-Hansen P; Pascual J
    Cephalalgia; 2015 Apr; 35(4):366-7. PubMed ID: 25022695
    [No Abstract]   [Full Text] [Related]  

  • 15. Atogepant (Qulipta®) for migraine prevention.
    Hay DL; Walker CS; Harris PWR
    Trends Pharmacol Sci; 2022 Aug; 43(8):701-702. PubMed ID: 35469689
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical Efficacy and Safety of Ubrogepant for the Acute Treatment of Migraine.
    Dodick DW; Ailani J
    J Fam Pract; 2020; 69(1 Suppl):S13-S22. PubMed ID: 32053715
    [No Abstract]   [Full Text] [Related]  

  • 17. Rimegepant: First Approval.
    Scott LJ
    Drugs; 2020 May; 80(7):741-746. PubMed ID: 32270407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
    Favoni V; Giani L; Al-Hassany L; Asioli GM; Butera C; de Boer I; Guglielmetti M; Koniari C; Mavridis T; Vaikjärv M; Verhagen I; Verzina A; Zick B; Martelletti P; Sacco S;
    J Headache Pain; 2019 Mar; 20(1):27. PubMed ID: 30866804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rimegepant for the treatment of migraine.
    Negro A; Martelletti P
    Drugs Today (Barc); 2020 Dec; 56(12):769-780. PubMed ID: 33332483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ubrogepant: First Approval.
    Scott LJ
    Drugs; 2020 Feb; 80(3):323-328. PubMed ID: 32020557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.